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Triosephosphate isomerase deficiency is associated with the accumulation of dihydroxyacetonephosphate (DHAP) to abnormally high
levels, congenital haemolytic anaemia and a clinical syndrome of progressive neuromuscular degeneration leading to infant mortality. DHAP
degrades spontaneously to methylglyoxal (MG)—a potent precursor of advanced glycation endproducts (AGEs). MG is detoxified to D-
lactate intracellularly by the glyoxalase system. We investigated the changes in MG metabolism and markers of protein glycation, oxidation
and nitrosation in a Hungarian family with two germline identical brothers, compound heterozygotes for triosephosphate isomerase
deficiency, one with clinical manifestations of chronic neurodegeneration and the other neurologically intact. The concentration of MG and
activity of glyoxalase I in red blood cells (RBCs) were increased, and the concentrations of D-lactate in blood plasma and D-lactate urinary
excretion were also increased markedly in the propositus. There were concomitant increases in MG-derived AGEs and the oxidative marker
dityrosine in hemoglobin. Smaller and nonsignificant increases were found in the neurologically unaffected brother and parents. There was a
marked increase (15-fold) in urinary excretion of the nitrosative stress marker 3-nitrotyrosine in the propositus. The increased derangement of
MG metabolism and associated glycation, oxidative and nitrosative stress in the propositus may be linked to neurodegenerative process in
triosephosphate isomerase deficiency.
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1. Introduction of homozygous or compound heterozygous deficiency isTriosephosphate isomerase (EC 5.3.1.1, TPI) deficiency
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E-mail address: thorp@essex.ac.uk (P.J. Thornalley).characterised by extraordinary low activities of TPI in many
tissues and is associated with chronic hemolytic anemia and
neuromuscular disorders originating from focal degenerative
processes of groups of neurons in different areas of the brain.
Onset occurs in childhood ( < 2 years old) and the majority of
cases die within 6 years. The cellular and physiological
characteristics of the TPI deficiency syndrome involve loss
of neurones from the dentate hypothalamus and medulla
oblongata and hyaline deposits throughout the hypothalamus
and cerebellar cortex, degeneration of vascular endothelial
cells and pericytes, and muscle fibre atrophy and regenera-
tion. Recurrent infections, cardiomyopathy and severe and
progressive neuromuscular disease lead to death [1].
TPI is coded by a single gene, TPI1, on chromosome
12p13. Thirteen mutations have been reported—the most
common occurring at Glu-104 (GAG:Glu!GAC:Asp) [2].
Recently, one of us began a study of two Hungarian brothers
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both brothers had identical genotypes and were compound
heterozygotes for two previously unknown mutations. One
of the mutations was at position 240 with Phe replacement
by Leu (TTC: Phe!CTC: Leu), creating a thermolabile
protein. The other mutation decreased the abundance of TPI
mRNA 10–20 fold [3]. This was later shown to be a
nonsense mutation, 145 (GAG:Glu!TAG:Stop) [4]. The
brothers are of interest in the mechanism of development of
the complications of TPI deficiency since one brother has the
expected neurological clinical syndrome and continuingFig. 1. (a) Triosephosphate metabolism to the formation and the formation and me
RBCs of TPI deficient family members. Data are meanF S.E. (n= 3 replicates) esurvival into his third decade whereas the other is neurolog-
ically asymptomatic. The red blood cells (RBCs) of both
siblings had < 3% of normal TPI activity and a 30–50-fold
increased concentration of dihydroxyacetonephosphate
(DHAP) in RBCs [5,6].
The most profound biochemical feature of TPI deficiency
is the dramatic increase in the cellular concentration of
DHAP. The high concentrations of DHAP, or a derivative
of it, for many years has been viewed as the cause of
morbidity in TPI deficiency [7,8]. This hallmark of the TPI
deficiency syndrome, and recent evidence of depletion oftabolism of MG. (b) Concentration of MG and (c) activity of glyoxalase I in
xcept control value (hatched bar) is the meanF S.E. (n= 21 subjects).
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that abnormal accumulation of methylglyoxal (MG) may be
associated with the clinical TPI deficiency syndrome. MG is
formed by the spontaneous degradation of DHAP—and also
from glyceraldehyde-3-phosphate (GA3P) [10]—and is de-
toxified by conversion to D-lactate catalysed by the gluta-
thione-dependent glyoxalase system [11]—Fig. 1a.
Increased concentrations of DHAP and decreased cellular
reduced glutathione are conditions ripe for MG accumula-
tion [12]. MG is a potent glycating agent of proteins and
precursor of advanced glycation endproducts (AGEs)
[13,14]. MG-derived AGEs are the hydroimidazolone Ny-
(5-hydro-5-methyl-4-imidazolon-2-yl)ornithine (MGH1),
Nq-(1-carboxyethyl)lysine (CEL), MG-derived lysine dimer
(MOLD) and argpyrimidine. Oxidative stress in TPI defi-
ciency may increase the formation of glyoxal which is also
detoxified by the glyoxalase system [11]. Glyoxal-derived
AGEs are the hydroimidazolone Ny-(5-hydro-4-imidazolon-
2-yl)ornithine (G-H1), Nq-carboxymethyl)lysine (CML) and
glyoxal-derived lysine dimer (GOLD); CML may also be
formed by the degradation of fructosyl-lysine, other keto-
amines and ascorbic acid [15].
We investigated the involvement of MG in TPI deficien-
cy by studying the RBC activity of glyoxalase I and II and
the concentrations of MG, MG-derived AGEs and other
protein biomarkers, and D-lactate in the RBCs, plasma and
urine of the TPI deficient brothers, a further unaffected
brother (simple heterozygote), their unaffected parents and
normal healthy controls. There were derangement of MG
metabolism and indications that oxidative and nitrosative
stress are involved in the neurodegenerative symptoms of
the TPI deficiency syndrome.2. Materials and methods
2.1. Materials
High-purity MG was prepared by acid hydrolysis of
methylglyoxal dimethylacetal and purified by fractional
distillation under reduced pressure [16]. Glyoxal solution
was purchased from Sigma. Nq-Fructosyl-lysine (FL), MG-
derived AGEs (MG-H1, CEL, MOLD and argpyrimidine),
glyoxal-derived AGEs (G-H1, CML and GOLD), pentosi-
dine, the markers of oxidative stress, methionine sulfoxide
(MetSO) and dityrosine, the marker of nitrosative stress, 3-
nitrotyrosine, and 6-aminoquinolyl-N-hydroxysuccinimidyl-
carbamate (AQC) were prepared as described [15,17–19].
[guanidino-15N2]-MG-H1 and [guanidino-
15N2]-G-H1 were
prepared from [guanidino-15N2]-L-arginine after conversion
to the Na-t-BOC-derivative [20]. [
13C6]-CEL and [
13C6]-
CML were prepared from [13C6]-L-lysine, and [
2H8]-MOLD,
[2H8]-GOLD and [
2H4]-fructosyl-lysine were prepared from
[4,4,5,5-2H4]-L-lysine after conversion to the Na-formyl
derivative [21]. Synthetic methods for the preparation, puri-
fication and characterisation of these AGE calibration stand-ards were as described for their non-isotopically substituted
analogues [15]. [methyl-2H3]-MetSO was prepared from
[methyl-2H3]-L-methionine, and [
2H6]-dityrosine and [
2H3]-
3-nitrotyrosine were prepared from ring-[2H4]-L-tyrosine, by
the methods described [17–19]. Isotopically substituted
standard amino acids were purchased from Cambridge
Isotope Laboratories (Andover, MA, USA).
2.2. Familial human subjects in the Hungarian family with
triosephosphate isomerase deficiency
The characteristics of the Hungarian family with TPI
deficiency studied have been described [5,22]. Briefly, the
TPI substitutions are: mother 240 Phe!Leu, father 145
Glu! Stop, propositus and compound heterozygote brother
have both substitutions, and simple heterozygote son 240
Phe!Leu. The parents and the simple heterozygote son
have RBC TPI activity around 50% of the normal range. The
propositus and compound heterozygote have the same level
of well-compensated hemolytic anemia but only the propos-
itus has characteristic neurological symptoms (severe extra-
pyramidal disorder). Blood samples and 24-h urine samples
from family and control subjects were taken with informed
consent. Venous blood samples were taken with heparin
anticoagulant and blood cells sedimented by centrifugation
(2000 g, 10 min). The plasma and buffy coat were re-
moved. Aliquots (0.25 ml) of plasma and packed RBCs for a-
oxoaldehyde analysis were acidified with 1 volume of 500
mM acetic acid. Acidified and non-acidified samples (for
glyoxalase activity, D-lactate and protein biomarker assays)
were snap-frozen in liquid nitrogen and stored at  80jC
prior to analysis, with intervening shipment between collab-
orating laboratories on cardice. Normal healthy control sub-
jects had a median age of 26 years, range 24–47 years
(n = 21).
2.3. Glyoxalase activity and metabolite assays
The activities of glyoxalase I and glyoxalase II in red
blood lysates were determined as described [23], referencing
activity to sample content haemoglobin determined by the
Drabkin method. The concentration of D-lactate in blood
plasma and urine was determined by endpoint enzymatic
assay with D-lactic dehydrogenase in neutralised perchloric
acid extracts [24]. MG and glyoxal contents of plasma and
RBCs were determined by derivatisation with 1,2-diamino-
4,5-dimethoxybenzene and HPLC of the resulting quinoxa-
line adducts with fluorimetric detection. Stock solutions of
MG and glyoxal stock solutions were calibrated by endpoint
enzymatic assay with glyoxalase I [25].
2.4. Protein biomarker determination by LC-MS/MS
Biomarkers of early-stage protein glycation (fructosyl-
lysine FL) and advanced-stage protein glycation (AGEs),
oxidative stress and nitrosation were determined in enzymatic
N. Ahmed et al. / Biochimica et Biophysica Acta 1639 (2003) 121–132124hydrolysates of hemoglobin and free in blood plasma and
urine. Analytes were measured by liquid chromatography
with triple quadrupole mass spectrometric detection (LC-MS/
MS), calibrated by stable isotope substituted standards
referenced to authentic analyte calibration curves. Nq-Fruc-
tosyl-lysine (FL), MG-derived AGEs (MG-H1, CEL and
MOLD), glyoxal-derived AGEs (G-H1, CML and GOLD),
the markers of oxidative stress, MetSO and dityrosine, and
the marker of nitrosative stress, 3-nitrotyrosine, were deter-
mined. Free protein markers in blood plasma and urine were
determined by assay of analytes in ultrafiltrate (12 kDa filter
cut-off, 50 Al aliquot) of plasma and urine. Protein bio-
markers in hemoglobin were determined in enzymatic digests
of hemoglobin of RBC lysates. Lysate was diluted with water
to 10mg/ml haemoglobin and an aliquot (500 Al) was washed
by three cycles of concentration and dilution by ultrafiltra-
tion. A portion (100 Ag) was then hydrolysed exhaustively by
consecutive incubation with pepsin, pronase E, and finally
aminopeptidase and prolidase, as described [15]. All steps at
pH 7.4 were performed under carbon monoxide to prevent
heme-catalysed oxidations during the hydrolysis.
Samples were assayed by LC-MS/MS using Waters 2690
Separation module with a Quattro Ultima triple quadrupole
mass spectrometric detector (Waters-Micromass, Manches-
ter, UK). AGE analytes were determined without derivatisa-
tion since for analytes MG-H1, G-H1, CML and CEL
derivatisation led to transfer of the a-oxoaldehyde-derived
moiety in the isotopically labelled standard to unlabelled
lysine and arginine in the sample and compromise of the
stable isotope calibration. Samples were also derivatised
with AQC prior to analysis since this provided required
increased sensitivity for dityrosine. For underivatised analy-
tes, two 5-Am Hypercarbk columns (Thermo Hypersil Ltd.,
Runcorn, UK) in series were used: 2.1 50 mm (column 1)Table 1
Chromatographic retention times and mass spectrometric multiple reaction monit
Analyte Rt (min) Parent
ion (Da)
Fragment
ion (Da)
Neutral fragment loss(es)
Lysine 5.0 147.1 84.3 H2CO2, NH3
CML 6.7 204.9 130.1 NH2CH(CH3)CO2H
MetSO 6.8 166.1 102.2 CH3-SOH
CEL 7.0 219.2 130.1 NH2CH(CH3)CO2H
FL 7.0 291.0 84.3 H2CO2, fructosylamine
Arginine 10.9 175.2 70.3 H2CO2, NH2C( =NH)NH2
GOLD 23.6 327.1 198.3 NH2CH(CO2H)CH2CH2CH=
MG-H1 23.6 and
24.0
229.2 114.3 NH2CH(CO2H)CH2CH=CH2
MOLD 24.4 341.2 212.3 NH2CH(CO2H)CH2CH2CH=
G-H1 25.0 215.0 100.2 NH2CH(CO2H)CH2CH=CH2
Tyrosine 26.9 182.1 136.2 H2CO2
Dityrosine 26.9 361.2 315.3 H2CO2
Methionine 8.2 150.0 104.2 H2CO2
3-Nitrotyrosine 22.1 227.1 181.2 H2CO2
AQC-derivatised analyte:
Dityrosine 30.7 701.3 531.4 8-Isocyanatoquinoline
The two epimeric forms of MG-H1 were resolved and hence the Rt values for boand 2.1 250 mm (column 2). The mobile phase was 26
mM ammonium formate, pH 3.8, with a gradient of 0–50%
acetonitrile from 17 to 30 min and isocratic 50% acetonitrile
from 30 to 40 min; the column was washed with 30%
isopropanol from 40 to 50 min and re-equilibrated with
initial mobile phase from 50 to 60 min. The flow rate was
0.2 ml/min. The flow was diverted from column 2 at 17 min
to facilitate elution of hydrophobic biomarkers and column
washing, and diverted back through columns 1 and 2 after 56
min to complete column washing and re-equilibration. Flow
from the column in the interval 4–40 min was directed to the
MS/MS detector. For AQC derivatised dityrosine, the col-
umn was a SymmetryTM 3.5-Am ODS, 2.1100 mm. The
mobile phases were: A—10 mM ammonium acetate with 5%
methanol, pH 4.8, and B—10 mM ammonium acetate with
95% methanol, pH 4.8. The elution profile was: 0–12 min,
isocratic 10% B; 12–20 min, linear gradient of 10–40% B;
20–38 min, isocratic 40% B; 38–48 min, 100% B (column
washing); and 48–55 min, re-equilibration with 10% B. The
flow rate was 0.2 ml/min and flow from the column in the
interval 4–38 min was directed to the detector.
Biomarkers were detected by electrospray positive ion-
isation-mass spectrometric multiple reaction monitoring.
The ionisation source temperature was 120 jC and the
desolvation gas temperature 350 jC. The cone gas and
desolvation gas flow rates were 150 and 550 l/h, respective-
ly. The capillary voltage was 3.55 kVand the cone voltage 80
V. Argon gas (2.7 10 3 mbar) was in the collision cell and
programmed molecular ion, fragment ion and collision
energies optimised to F 0.1 Da and F 1 eV for multiple
reaction monitoring detection and are given with neutral
fragment losses in Table 1. Amounts of internal standard
used were: 10 nmol for amino acids, 250 pmol for FL, and
10–50 pmol for glycation, oxidation and nitrosation bio-oring detection of protein biomarkers
Internal standard Isotopic
purity (%)
Parent
ion (Da)
Fragment
ion (Da)
CE
(eV)
[13C6]-Lysine 83.9 (0.7) 153.1 89.3 15
[13C6]-CML 68.6 (1.4) 210.9 136.1 12
[methyl-2H3]-MetSO 99.5 (0.5) 169.1 102.2 14
[13C6]-CEL 82.5 (2.4) 225.2 136.1 13
[2H4]-FL 90.5 (0.6) 295.0 88.3 31
[15N2]-Arginine 96.4 (3.6) 177.2 72.3 15
CH2 [
2H8]-GOLD 84.3 (3.1) 335.1 202.3 21
[15N2]-MG-H1 96.1 (3.1) 231.2 116.3 14
CH2 [
2H8]-MOLD 83.0 (0.3) 349.2 216.3 21
[15N2]-G-H1 94.5 (2.7) 217.0 102.2 14
[ring-2H4]-Tyrosine 94.0 (0.5) 186.1 140.2 13
[ring-2H6]-Dityrosine 80.9 (1.8) 367.2 321.3 15
[methyl-2H3]-Methionine 99.1 (0.5) 153.0 107.2 11
[ring-2H3]-3-Nitrotyrosine 95.7 (0.1) 230.1 184.2 13
[ring-2H6]-Dityrosine 93.4 (0.3) 707.3 537.4 23
th are given.
N. Ahmed et al. / Biochimica et Biophysica Acta 1639 (2003) 121–132 125markers. Limits of detection were 0.2–1 pmol, interbatch
coefficients of variation 2–16% (n = 6) and analyte recover-
ies in the enzymatic hydrolysis >90% (except 71% for FL
and 54% for G-H1), depending on the analyte.
2.5. Assay of pentosidine and argpyrimidine by HPLC
detection of intrinsic fluorescence
The pentosidine contents of hemoglobin, plasma and
urine were determined without derivatisation by HPLC with
a Waters 2475 fluorescence detector. The column was of 5-
Am particle size, 50 2.1 mm Hypercarb (Thermo-Hyper-
sil-Keystone, Runcorn, UK). The mobile phase was 0.1%
trifluoroacetic acid with 10% acetonitrile, a linear gradient
to 50% acetonitrile at 15 min and isocratic 50% acetonitrile
thereafter. For pentosidine and argpyrimidine, the retention
times were 32.8 and 31.0 min and the limits of detection 30
and 400 fmol, respectively.3. Results
3.1. Increased RBC MG concentration in triosephosphate
isomerase deficiency
Increased concentration of DHAP in TPI deficiency may
give rise to increased formation ofMG [10].Wemeasured the
concentrations of MG and glyoxal in RBCs of the Hungarian
family with the TPI deficiency trait. The concentration ofMG
in RBCs was increased significantly in the propositus (59%,
P < 0.01), with respect to normal healthy controls; it was
increased in the neurologically unaffected brother, mother,
father and simple heterozygote but not significantly from the
normal control value. The concentration of MG in RBCs was
higher in the propositus than in the compound heterozygote
(P < 0.05)—Fig. 1b. There concentration of glyoxal in RBCs
was not increased significantly in any family member, with
respect to normal controls. The MG and glyoxal concen-
trations in RBC of normal control subjects were 445F 177
and 826F 504 pmol/ml RBCs, respectively (n = 21). The
concentrations of MG and glyoxal in blood plasma were not
increased significantly in any family member, with respect to
that of normal control subjects.
MG and glyoxal are substrates for glyoxalase I. RBC
glyoxalase I activity was increased significantly in the
propositus (58%, P < 0.001) and simple heterozygote
(33%, P < 0.05) with respect to the glyoxalase I activity of
normal healthy controls—Fig. 1c. The RBC glyoxalase I
activity in normal controls was 0.273F 0.069 U/mg Hb
(n = 21). There was no significant change in RBC glyoxalase
II activity in any family members. The RBC glyoxalase II
activity in normal controls was 0.062F 0.009 U/mg Hb
(n = 21).
The major metabolic fate of MG is conversion to D-
lactate catalysed by the glyoxalase system [11]. We there-
fore investigated the concentrations of D-lactate in bloodplasma and urine of family members and normal control
subjects. Plasma D-lactate was increased markedly in the
propositus (250%, P < 0.001) and moderately in the com-
pound heterozygote (182%, P < 0.001), with much smaller
increases in the mother (64%, P < 0.01) and father (69%,
P < 0.01), with respect to the normal control levels. Plasma
D-lactate concentration was higher in the propositus than in
the compound heterozygote (P < 0.01)—Fig. 2a. The con-
centration of D-lactate in blood plasma of normal healthy
control subjects was 12.5F 5.4 AM (n = 21). A similar
effect was observed for 24-h urinary D-lactate where the D-
lactate elimination was increased 325% in the propositus
(P < 0.001), 75% in the compound heterozygote (P < 0.05)
and not increased significantly in both parents, with respect
to value in normal controls—Fig. 2b. Urinary D-lactate
excretion in normal, healthy human subjects was 27.9F
13.6 Amol/24 h (range 9.0–52.5).
3.2. Accumulation of MG-derived AGEs and biomarkers of
oxidative and nitrosative stress in triosephosphate
isomerase deficiency
The prolonged accumulation of MG in RBCs of the
propositus may give rise to increased formation of AGEs
which may, in turn, reflect the severity of increased MG
exposure of the 6–8 weeks prior to sampling. These and
markers of protein oxidative damage (MetSO and dityr-
osine) and nitrosative damage (3-nitrotyrosine) were
assayed in hemoglobin and free in blood plasma and
urine of family members and normal control subjects—
Figs. 3–6. Specimen analytical chromatograms for analy-
tes and stable isotope-substituted standards are given in
Fig. 4a–h.
For MG-derived protein biomarkers, MG-H1 in hemo-
globin was increased in all family members but only signif-
icantly in the propositus (49%), compound heterozygote
(48%) and simple heterozygote (35%), with respect to
normal control subjects. MG-H1 was significantly higher
in the propositus (P < 0.01) and compound heterozygote
(P < 0.05) than in the simple heterozygote—Fig. 5a. The
concentration of MG-H1 (meanF S.D.) in normal control
subjects was 1.47F 0.49% Hb (n = 11). CEL was increased
significantly in all family members (P < 0.001): fivefold in
the mother, threefold in the father, sevenfold in the propos-
itus, fivefold in the compound heterozygote and fourfold in
the simple heterozygote—Fig. 5b. The concentration of CEL
(meanF S.D.) in normal control subjects was 0.24F 0.16%
Hb (n = 11). MOLD was also increased in all family mem-
bers, and was highest in the propositus at 0.083% Hb—Fig.
5c. The concentration of MOLD in normal healthy human
subjects was 0.024F 0.023% Hb (n = 11). The concentration
of argpyrimidine was below the limit of detection ( < 0.35%
Hb) in all family members and control subjects. Surprisingly,
the concentration of FL was decreased in the propositus and
the compound heterozygote (3.35 and 4.09% Hb, P < 0.001,
respectively) with respect to the control value (7.66F 0.62%
 Fig. 3. Protein biomarkers of glycation, oxidation and nitrosation.
Fig. 2. Plasma and urinary D-lactate of TPI-deficient family members. (a) Plasma D-lactate, and (b) 24 h urinary D-lactate. Data are meanF S.E. (n= 3
replicates) except control value (hatched bar) is the meanF S.E. (n= 21 subjects).
N. Ahmed et al. / Biochimica et Biophysica Acta 1639 (2003) 121–132126
Fig. 4. Analytical chromatograms in the determination of protein biomarkers by LC-MS/MS in the propositus. Protein biomarkers: (a) CEL, Rt 7.3 min; (b)
fructosyl-lysine, Rt 7.5 min (extensive peak tailing was observed); (c) MG-H1, Rt 23.7 and 24.2 min (two epimers resolved); (d) Dityrosine, Rt 29.4; (e) 3-
Nitrotyrosine, Rt 32.4 min; (f) [13C6]-CEL (5 pmol); (g) [
4H2]-fructosyllysine (125 pmol); (h) [
15N2]-MG-H1 (25 pmol); (i) [
6H2]-dityrosine (12.5 pmol); and
(j) [3H2]-3-nitrotyrosine (5 pmol). Chromatographic conditions were described in Section 2.
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AGEs, CML, G-H1 and GOLD, were also analysed. CML
was 0.34F 0.10% Hb in the control subjects (n = 11) and
was not changed significantly in any family member. G-H1and GOLD were below the limits of detection in all samples
( < 0.3% Hb and < 0.2% Hb, respectively). The AGE pento-
sidine, often viewed as a general marker of advanced
glycation, accounted for 0.096F 0.029% Hb in the normal
Fig. 5. Concentration of protein glycation biomarkers in hemoglobin of TPI deficient family members. (a) MG-H1, (b) CEL, (c) MOLD and (d) FL. Data are
meanF S.E. (n= 3 replicates) except control value (hatched bar) is the meanF S.E. (n= 11 subjects).
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any family member. The biomarkers of oxidative damage,
MetSO and dityrosine were also investigated. MetSO was ca.
1.06F 0.15% Hb (n = 11) in normal healthy controls and
was not changed significantly in any family member. In
contrast, dityrosine was 0.42% Hb in the normal healthycontrol subjects and was increased significantly (61%) in the
propositus only—Fig. 6a.
We investigated the concentrations of free protein bio-
markers in plasma since these may be released by protein
turnover from tissues suffering metabolic derangement in
TPI deficiency. Such measurements are complicated, how-
Fig. 6. Protein biomarkers of oxidation, glycation and nitrosation. (a) Concentration of dityrosine in hemoglobin, (b) plasma MG-H1 and (c) urinary 3-
nitrotyrosine of TPI deficient family members. Data are meanF S.E. (n= 3 replicates) except control value (hatched bar) is the meanF S.E. (n= 11 subjects).
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and renal clearance of biomarkers. Biomarker concentrations
were generally within the range found in normal healthy
controls except for MG-H1 which was increased fivefold in
the propositus (P < 0.01) and threefold in the compound
heterozygote (P < 0.01)—Fig. 6b. Similarly, the urinary
output of biomarkers of family members was generally
within the range of normal healthy controls except that 3-
nitrotyrosine was increased 15-fold in the propositus—Fig.
6c. This marked increase of urinary 3-nitrotyrosine in the
propositus was retained when estimates were normalised to
urinary creatinine. Urinary 3-nitrotyrosine (nmol/mmol cre-
atinine): mother 4.58F 0.97, father 4.78F 1.03, propositus
35.6F 2.5, compound heterozygote 2.80F 0.94 and control
5.16F 0.67. 3-Nitrotyrosine was also determined in blood
plasma. The concentration was 9.4F 0.4 nM in controls and
was not changed significantly in any family member.4. Discussion
The spontaneous degradation of triosephosphates is con-
sidered to be the major source of formation of MG in vivo in
normal healthy subjects [10,11]. In TPI deficiency there was
the expectation, therefore, that MG formation may be in-
creased and this would produce increased concentrations of
MG and MG-derived AGEs. The concentrations of DHAP in
RBCs of the propositus and compound heterozygote were
typically 70- and 45-fold higher than normal, and in the
parents ca. one- to twofold higher than normal. The increase
in the concentration of MG in RBCs of the propositus was
relatively modest, and increases in other family members
were generally within the highest quartile of the normal
range. Normally ca. 40–67% of MG is formed from GA3P
and 33–60% from DHAP, depending on the DHAP/GA3P
molar ratio (4–12). In TPI deficiency, the concentration of
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markedly. The specific reactivity towards fragmentation of
DHAP to MG decreases because it hydrates fully. The
minimum expected increase in MG formation (for a 45-fold
increase in DHAP concentration, a DHAP/GA3P molar
ratio = 4 and attainment of DHAP hydration equilibrium)
is ca. eightfold. The metabolism of D-lactate may increase
twofold such that the remaining urinary D-lactate is pre-
dicted to increase fourfold, as observed. The derangement of
glyoxalase metabolites found in the propositus may be in
keeping with increased degradation of DHAP to MG. MG
concentration was only increased modestly because of the
efficiency of its detoxification by the glyoxalase system; the
assay methodology used to measure MG herein measures
the sum of MG in free solution and bound reversibly to
protein (mainly on protein thiols) [25,26]. Increased plasma
and urine of D-lactate of the propositus suggests that the
propositus sustains a particularly high flux of MG forma-
tion. The small but significant increases in plasma D-lactate
of both parents may reflect the moderate increases in DHAP
in these subjects, with respect to controls. The estimates of
DHAP and MG-related variables in the propositus, com-
pound heterozygote and normal controls has been summar-
ised in Table 2.
A further independent measure of increased MG exposure
comes from the levels of MG-derived AGEs. When the AGE
is formed irreversibly with a chemical stability much greater
than the lifespan of RBCs, as applies for CEL andMOLD, the
AGE levels are expected to reflect exposure to MG in the 6–
8 weeks prior to sampling. When the AGE is formed
reversibly and has chemical stability less than the RBC
lifespan, as applies for MGH1 (with a half-life of ca. 12 days
under physiological conditions), the AGE level reflected MGTable 2
Metabolites in blood plasma and red blood cells of the triosephosphate
isomerase deficient propositus, compound heterozygote and normal healthy
controls
Analyte Compartment
(units)
Propositus Compound
heterozygote
Normal
controls
TPI activityy RBCs (U/g Hb) 9.4 6.1 1364–1793
DHAPy RBCs (nmol/ml
RBCs)
905 581 5.1–13.0
DHAP!MG Proportion
of DHAP (%)
3.6 2.3 0.5
MG RBCs (pmol/ml
RBCs)
724 625 455F 157
Plasma (pmol/ml) 180 198 139F 98
RBCs (nmol/ml
RBCs)
31.4 24.7 8.8F 3.8
D-Lactate Plasma (nmol/ml) 44.8 35.3 12.5F 5.4
Urine (Amol/24 h) 119 49 28F 14
y Data taken from Ref. [22]; otherwise from this work. The proportion
of DHAP metabolised to methylglyoxal was deduced from previous
measurements with RBC incubations in culture with and without added
dihydroxyacetone, which is rapidly converted to DHAP by triokinase. The
flux of methylglyoxal formation was estimated by the increase in D-lactate
concentration; D-lactate is not metabolised in RBCs [34].exposure in this shorter period (2–4 weeks) [15]. The
increased levels of Hb MG-H1, CEL and MOLD reflect
exposure to increased levels of MG in the medium term in all
family members with the highest increases and severity of
MG levels in the propositus and compound heterozygote.
The estimation of FL adducts in hemoglobin by LC-MS/
MS gave high estimates for FL. Most fructosamine-modified
Hb has a h-chain terminal N-fructosyl-valine residues that
represents ca. 60% of total glycated hemoglobin HbA1; FL
residues are mainly on the a-chains and represent ca. 40% of
glycated hemoglobin HbA1 [27]. Assay of HbA1 by mass
spectrometric techniques gives estimates approximately
twice that determined by affinity and ion exchange separa-
tion techniques because intact glycated subunits of Hb
retained on chromatography columns undergo subunit ex-
change such that the HbA1 eluted has greater than one
fructosamine adduct per Hb tetramer [27]. The concentration
of FL was decreased in the propositus and compound
heterozygote in the absence of evidence of hypoglycemia
in these subjects. This may be a feature of oxidative stress in
the normoglycemic status of TPI deficiency where increased
oxidative degradation of FL occurs. The marker of oxidative
damage to protein, dityrosine [28], was increased signifi-
cantly in the propositus—consistent with the oxidative stress
in TPI deficiency. MetSO was not increased similarly but this
may be due to the countering effects of MetSO reductase
activity repairing the oxidative damage [29].
Cellular proteins containing MG-H1 and CEL residues
are degraded and the free AGEs are released into the
circulation for urinary excretion; AGEs in plasma proteins
may be removed by degradation of plasma protein by renal
tubular epithelial cells after leakage into the glomerular
filtrate. The plasma concentration of MG-H1, however,
was increased in the plasma of the propositus and compound
heterozygote. Increased glycation of proteins by MG is
associated with enzyme inactivation, protein denaturation
and cross-linking [11,13,13,30]. This may contribute to the
TPI deficiency syndrome.
3-Nitrotyrosine was determined as a marker of protein
nitrosation mediated by reactions of peroxynitrite and nitryl
chloride [31]. This marker was below the limit of detection
in hemoglobin ( < 0.05% Hb) but it was found free in
plasma at concentrations similar to those reported [32].
The urinary excretion of 3-nitrotyrosine was increased from
control levels only in the propositus. Increased protein
nitrosation has been linked to cholinergic dysfunction
occurring in neurodegenerative diseases where formation
of 3-nitrotyrosine was associated with inhibition of acetyl-
choline synthesis and choline acetyltransferase [33]. In-
creased activity of acetylcholine esterase was found in an
earlier study in the red cell membrane preparations of the
neurologically affected Hungarian patient with TPI deficien-
cy as compared to his neurologically symptom-free brother
and normal controls [22]. The neuromuscular disorders seen
in TPI deficiency syndrome may be mediated by increased
tyrosine nitration.
N. Ahmed et al. / Biochimica et Biophysica Acta 1639 (2003) 121–132 131The two brothers studied have germ-line identical TPI,
suffer from severe TPI deficiency, but only one developed
neurological disorders. The neurologically intact compound
heterozygote had a lower MG concentration in RBCs, a
lower plasma D-lactate concentration and lower urinary D-
lactate than the propositus. This suggests that the exposure
to high fluxes of MG was lower in the compound hetero-
zygote than in the propositus. Increased MG accumulation
and glycation in the propositus may contribute directly to
the pathogenesis of the neurodegeneration.Acknowledgements
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